Federal Register of Legislation - Australian Government

Primary content

PB 100 of 2019 Determinations/Health as made
This instrument amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010) by adding a new brand premium to two brands of two pharmaceutical items in addition to an administrative amendment to the form description of one brand of one pharmaceutical item. It also removes one brand of one pharmaceutical item that will no longer be Pharmaceutical Benefits Scheme listed on 1 December 2019.
Administered by: Health
Registered 27 Nov 2019
Tabling HistoryDate
Tabled HR28-Nov-2019
Tabled Senate02-Dec-2019
To be repealed 24 Mar 2020
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 100 of 2019

 

National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 11)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

 

Dated      27 November 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 


_________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 11).

(2)          This Instrument may also be cited as PB 100 of 2019.

2          Commencement

This Instrument commences on 1 December 2019.

3          Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

 


Schedule 1     Amendments

[1]   Schedule 1, after entry for Fluoxetine in the form Tablet, dispersible, 20 mg (as hydrochloride)

insert:

Fluticasone propionate with salmeterol

Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)

Inhalation by Mouth

Seretide MDI 125/25

1

34.56

38.28

 

Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)

Inhalation by Mouth

Seretide MDI 250/25

1

46.78

50.50

[2]   Schedule 1, entry for Triamcinolone with Neomycin, Gramicidin and Nystatin

omit:

 

Ear drops containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 7.5 mL

Application to the ear

Kenacomb Otic

1

3.78

5.36

substitute:

 

Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per g, 7.5 mL

Application to the ear

Kenacomb Otic

1

3.78

5.36

[3]   Schedule 1, entry for Trimethoprim with Sulfamethoxazole

omit:

 

Tablet 160 mg‑800 mg

Oral

Bactrim DS

10

1.76

3.78

 

 

 

Septrin Forte

10

1.76

5.64

substitute:

 

Tablet 160 mg‑800 mg

Oral

Septrin Forte

10

1.76

5.64